open access

Vol 53, No 3 (2022)
Original research article
Submitted: 2021-10-24
Accepted: 2022-03-21
Published online: 2022-06-06
Get Citation

Survival in patients with multiple myeloma: a real-life single-center study

Marek Rodzaj1, Anna Morawska-Krekora2, Malgorzata Razny2, Beata Jakubas3
DOI: 10.5603/AHP.a2022.0024
·
Acta Haematol Pol 2022;53(3):201-206.
Affiliations
  1. Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, Garncarska 11, 31-115 Kraków, Poland
  2. Department of Hematology and Internal Diseases, The Rydygier Hospital., os. Zlotej Jesieni 1, 31-810 Krakow, Poland
  3. Department and Division of Hematology, Jagiellonian University Medical College, Świętej Anny 12, 31-008 Krakow, Poland

open access

Vol 53, No 3 (2022)
ORIGINAL RESEARCH ARTICLE
Submitted: 2021-10-24
Accepted: 2022-03-21
Published online: 2022-06-06

Abstract

Introduction: The development of novel drugs with a different mechanism of action has led to considerable progress in multiple myeloma (MM) treatment. However, the exact associations between overall survival (OS) and different treatment types, response to treatment, as well as clinical and laboratory parameters, have not been fully elucidated. We aimed to determine the effect of clinical and laboratory parameters, type of induction therapy, and high-dose chemotherapy with autologous hematopoietic stem-cell transplant (auto-HSCT) on OS in patients with MM. Material and methods: This retrospective study included 413 patients with MM treated between 2006 to 2017. Correlations between selected clinical and laboratory parameters and OS were assessed. The severity of MM was evaluated using the Durie-Salmon classification. Results: The median OS was 4.08 years. The overall response rate to chemotherapy was 76%. The complete remission (CR) rates were higher in patients receiving bortezomib-based therapy than in those receiving thalidomide-based therapy or standard chemotherapy (p < 0.001). The CR rate was positively correlated with OS. The use of auto-HSCT with bortezomib-based therapy was associated with longer OS. Renal failure and elevated urinary protein levels were inversely correlated with OS. The severity of MM at diagnosis was also associated with OS. The percentage of bone marrow  plasma cell infiltration did not correlate with OS. Conclusions: MM is still diagnosed too late, by which time patients have developed almost irreversible complications. However, we confirmed that novel treatments improve OS in these patients, especially when used in addition to auto-HSCT. These findings may facilitate clinical therapeutic decision making.

Abstract

Introduction: The development of novel drugs with a different mechanism of action has led to considerable progress in multiple myeloma (MM) treatment. However, the exact associations between overall survival (OS) and different treatment types, response to treatment, as well as clinical and laboratory parameters, have not been fully elucidated. We aimed to determine the effect of clinical and laboratory parameters, type of induction therapy, and high-dose chemotherapy with autologous hematopoietic stem-cell transplant (auto-HSCT) on OS in patients with MM. Material and methods: This retrospective study included 413 patients with MM treated between 2006 to 2017. Correlations between selected clinical and laboratory parameters and OS were assessed. The severity of MM was evaluated using the Durie-Salmon classification. Results: The median OS was 4.08 years. The overall response rate to chemotherapy was 76%. The complete remission (CR) rates were higher in patients receiving bortezomib-based therapy than in those receiving thalidomide-based therapy or standard chemotherapy (p < 0.001). The CR rate was positively correlated with OS. The use of auto-HSCT with bortezomib-based therapy was associated with longer OS. Renal failure and elevated urinary protein levels were inversely correlated with OS. The severity of MM at diagnosis was also associated with OS. The percentage of bone marrow  plasma cell infiltration did not correlate with OS. Conclusions: MM is still diagnosed too late, by which time patients have developed almost irreversible complications. However, we confirmed that novel treatments improve OS in these patients, especially when used in addition to auto-HSCT. These findings may facilitate clinical therapeutic decision making.

Get Citation

Keywords

autologous hematopoietic stem-cell transplant, bortezomib, chemotherapy, multiple myeloma, overall survival

About this article
Title

Survival in patients with multiple myeloma: a real-life single-center study

Journal

Acta Haematologica Polonica

Issue

Vol 53, No 3 (2022)

Article type

Original research article

Pages

201-206

Published online

2022-06-06

Page views

2072

Article views/downloads

172

DOI

10.5603/AHP.a2022.0024

Bibliographic record

Acta Haematol Pol 2022;53(3):201-206.

Keywords

autologous hematopoietic stem-cell transplant
bortezomib
chemotherapy
multiple myeloma
overall survival

Authors

Marek Rodzaj
Anna Morawska-Krekora
Malgorzata Razny
Beata Jakubas

References (9)
  1. Wildes TM, Rosko A, Tuchman SA. Multiple myeloma in the older adult: better prospects, more challenges. J Clin Oncol. 2014; 32(24): 2531–2540.
  2. Terpos E, Mikhael J, Hajek R, et al. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J. 2021; 11(2): 40.
  3. Mohty M, Terpos E, Mateos MV, et al. EMMOS Investigators. Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study. Clin Lymphoma Myeloma Leuk. 2018; 18(10): e401–e419.
  4. Sawyer JR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet. 2011; 204(1): 3–12.
  5. Dimopoulos MA, Moreau P, Palumbo A, et al. ENDEAVOR Investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016; 17(1): 27–38.
  6. Dimopoulos MA, Terpos E, Niesvizky R, et al. Clinical characteristics of patients with relapsed multiple myeloma. Cancer Treat Rev. 2015; 41(10): 827–835.
  7. Dmoszyńska A, Walter-Croneck A, Pieńkowska-Grela B, et al. Recommendations of Polish Myeloma Group concerning diagnosis and therapy of multiple myeloma and other plasmacytic dyscrasias for 2016. Acta Haematol Pol. 2016; 47(2): 39–85.
  8. Dancy E, Garfall A, Cohen A, et al. Clinical predictors of T cell fitness for CAR T cell manufacturing and efficacy in multiple myeloma. Blood. 2018; 132(Suppl 1): 1886–1886.
  9. Vincent Rajkumar S. Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014; 89(10): 999–1009.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: viamedica@viamedica.pl